US Markets Open

AI-assisted · Not financial adviceNot advice

AI-assisted · Not financial advice.

US Markets Open

AI-assisted · Not financial adviceNot advice

US Markets Open

AI-assisted · Not financial adviceNot advice

$LLY

Name: LLY (Eli Lilly) — Market Sentiment & Discussion
Creator: MarketMind
License: https://stockmarketsentimentai.com/methodology

Eli Lilly· 4/6/2026, 6:50:47 PM

Data Checks· 2 of 3 passed

Analyst target

19% upside · 13 analysts · $985–$1350 range

▲ $1244

Earnings

EPS: $34.43 → $42.02 (2026 vs 2027)

▲ Expected to grow 22%

Insiders (90d)

0 buys, 30 sells

Last: SELL Jan 7· 89d ago

▼Net selling $322.4M

Options positioning: Neutral — More betting on upside (1.2× more call than put volume today). Unusual bets on $750 downside — 133× normal activity. analysts: 33 buy vs 3 sell.

Reddit: MixedAttention: Elevated

Community Take (7D)

Retail sentiment is bullish on Eli Lilly's pipeline, but cautious about competition, aligning with news of stock downgrades. This suggests a need for careful evaluation of the company's future prospects.

News vs Reddit

Wait & See

News: divided · 60% qualityReddit: neutral · 0% confidence

The Story

News Summary

Eli Lilly faces stock downgrades and competition

Key Events

Mar 15, 2001:Stock splits are actions taken by corporations to make their shares nominally affordable for more retail investors.
Mar 16, 2001:Eli Lilly's Phase 3 results for Ebglyss in children with severe eczema show positive outcomes.
Mar 17, 2001:Eli Lilly shares fell 5% after HSBC downgraded the stock, raising concerns about the obesity drug market.

Sentiment: 70% bullish / 30% neutral (early) → 60% bearish / 30% cautious / 10% bullish (late)

Impact: Initially, the narrative was positive due to successful trial results for Ebglyss, but shifted to bearish following a stock downgrade by HSBC, raising concerns about future performance.

Risks: competition in the obesity drug market, stock downgrades affecting investor confidence

Analyst ConsensusBuy (45 analysts)

Target: $1244 avg (+19% upside)

33 Buy · 9 Hold · 3 Sell

Signal

Divided

Confidence

60%

Based on curated news sources (not retail comments)

Over the last 7 days: Eli Lilly shows strong leadership in the weight loss market and positive clinical trial results, but faces caution from analysts and safety concerns that could impact investor sentiment.

SentimentNeutral

AnalysisHype

Bullish Factors

✓Eli Lilly is the leader in the U.S. weight loss drug market, with a 60% share [FMP|Mar 17]
✓Positive Phase 3 results for EBGLYSS in pediatric patients with moderate-to-severe atopic dermatitis [FMP|Mar 16]
✓Eli Lilly is rated a strong buy with a $1,623 price target, driven by multiple near- and long-term catalysts [FMP|Mar 12]

Risk Factors

✗HSBC analysts have turned more cautious on Eli Lilly, arguing that expectations tied to the company's weight-loss drug opportunity could be running ahead [FMP|Mar 17]
✗Eli Lilly issued a public warning about potential safety risks linked to compounded tirzepatide products [FMP|Mar 12]
✗Eli Lilly's stock has pulled back sharply, falling 9% over the past month, and 13% year-to-date [FMP|Mar 17]

Analyze with AI yahoo!finance Reddit Answers

AI-assisted · Not financial advice.

$LLY - Eli Lilly | MarketMind | MarketMind

$LLY

Eli Lilly· 4/6/2026, 6:50:47 PM

Data Checks· 2 of 3 passed

Analyst target

19% upside · 13 analysts · $985–$1350 range

▲ $1244

Earnings

EPS: $34.43 → $42.02 (2026 vs 2027)

▲ Expected to grow 22%

Insiders (90d)

0 buys, 30 sells

Last: SELL Jan 7· 89d ago

▼Net selling $322.4M

Options positioning: Neutral — More betting on upside (1.2× more call than put volume today). Unusual bets on $750 downside — 133× normal activity. analysts: 33 buy vs 3 sell.

Reddit: MixedAttention: Elevated

Community Take (7D)

News vs Reddit

Wait & See

News: divided · 60% qualityReddit: neutral · 0% confidence

The Story

News Summary

Eli Lilly faces stock downgrades and competition

Key Events

Mar 15, 2001:Stock splits are actions taken by corporations to make their shares nominally affordable for more retail investors.
Mar 16, 2001:Eli Lilly's Phase 3 results for Ebglyss in children with severe eczema show positive outcomes.
Mar 17, 2001:Eli Lilly shares fell 5% after HSBC downgraded the stock, raising concerns about the obesity drug market.

Sentiment: 70% bullish / 30% neutral (early) → 60% bearish / 30% cautious / 10% bullish (late)

Impact: Initially, the narrative was positive due to successful trial results for Ebglyss, but shifted to bearish following a stock downgrade by HSBC, raising concerns about future performance.

Risks: competition in the obesity drug market, stock downgrades affecting investor confidence

Analyst ConsensusBuy (45 analysts)

Target: $1244 avg (+19% upside)

33 Buy · 9 Hold · 3 Sell

Signal

Divided

Confidence

60%

Based on curated news sources (not retail comments)

SentimentNeutral

AnalysisHype

Bullish Factors

✓Eli Lilly is the leader in the U.S. weight loss drug market, with a 60% share [FMP|Mar 17]
✓Positive Phase 3 results for EBGLYSS in pediatric patients with moderate-to-severe atopic dermatitis [FMP|Mar 16]
✓Eli Lilly is rated a strong buy with a $1,623 price target, driven by multiple near- and long-term catalysts [FMP|Mar 12]

Risk Factors

✗HSBC analysts have turned more cautious on Eli Lilly, arguing that expectations tied to the company's weight-loss drug opportunity could be running ahead [FMP|Mar 17]
✗Eli Lilly issued a public warning about potential safety risks linked to compounded tirzepatide products [FMP|Mar 12]
✗Eli Lilly's stock has pulled back sharply, falling 9% over the past month, and 13% year-to-date [FMP|Mar 17]

Analyze with AI yahoo!finance Reddit Answers